First-Line Zongertinib in Advanced <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

John V. Heymach

Noboru Yamamoto

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo

Nicolas Girard

Institut Curie, Institut du Thorax Curie-Montsouris, Paris

Gerrina Ruiter

Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam

Egbert F. Smit

David Planchard

Ernest Nadal

Thoracic Tumors Unit, Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L’Hospitalet de Llobregat, Barcelona

Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

Jon Zugazagoitia

Department of Medical Oncology, 12 de Octubre Hospital, Madrid

Hai-Yan Tu

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Christina S. Baik

Thoracic, Head and Neck Medical Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle

Kiyotaka Yoh

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Ross A. Soo

Department of Hematology–Oncology, National University Cancer Institute, Singapore

Yanqiu Zhao

Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

Joshua K. Sabari

Division of Medical Oncology, Perlmutter Cancer Center, New York University Langone Health, New York

Martin Wermke

National Center for Tumor Diseases–University Cancer Center Early Clinical Trial Unit, Technische Universität Dresden, Dresden, Germany

Matthias Scheffler

Myung-Ju Ahn

Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Kristie Fernamberg

Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

Lukas Schroeter

Boehringer Ingelheim Pharma, Biberach an der Riss, Germany

Behbood Sadrolhefazi

Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

Claus Thamer

Boehringer Ingelheim Pharma, Biberach an der Riss, Germany

Sabina Eigenbrod-Giese

Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Sanjay Popat